World's longest surviving liver-pancreas recipient by Harary, AM et al.
Fu 
I tapraid5/zI1-liver/zll-liver/zlto0807/zlt1331d07g I sangreyj I 8=416/5/07 114:50 I Art: 07-007 1 I 
LIVER TRANSPLANTATION 12:000-000. 2007 
World's Longest Surviving Liver-Pancreas 
Recipient 
Albert M. Harary,l Kareem Abu-Elmagd,2 Ngoc Thai,2 Ron Shapiro,2 Satoru Todo,2 John J. Fung,2 and 
Thomas E. Starzl2 
1 New York University School of Medicine and Lenox Hill Hospital, New York, NY, and 2 Thomas E. Starzl 
Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 
In July 1988, the liver and pancreas of a cadaveric donor were transplanted separately into a man with type 1 diabetes with 
end-stage chronic hepatitis B virus. Two features of the operation may help explain the patient's current status as the 
longest-lived liver-pancreas recipient. One was enteric drainage of pancreatic exocrine secretions. The other was delivery of 
the pancreas venous effluent to the host portal system and then directly to the hepatic allograft. Liver Transpl12:000-000, 
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Kidney and pancreas transplants from the same de-
ceased donor are frequently used to treat patients with 
renal failure caused by diabetic nephropathy. In con-
trast, combined transplantation of the liver and pan-
creas has been limited almost excluSively to nondia-
betic reCipients of abdominal multivisceral grafts. Here, 
we report simultaneous pancreas and liver transplan-
tation to a patient with type 1 diabetes mellitus whose 
unrelated end-stage hepatic disease was chronic hepa-
titis B virus (HBV)-associated cirrhosis. The patient is 
noteworthy because he is the longest surviving liver-
pancreas reCipient in the world. 1 The case illustrates 
some aspects of pancreas transplantation and their re-
lation to liver health that have not been fully clarified to 
the present day. 
CASE REPORT 
In 1963, a 15-year-old patient developed acute HBV 
hepatitis after the incomplete open heart repair of an 
atrioventricular (AV) defect in his native Poland. At 
the age of 29 years (and now in New York), he devel-
oped type 1 insulin-dependent diabetes mellitus that 
required treatment for the next 11 years with approx-
imately 70 U of insulin per day in diVided doses. 
Ongoing liver disease was not apparent until 1982. 
Analysis of a liver biopsy sample showed ,chronic ac-
tive hepatitis and macro- and micronodula.r cirrhosis. 
Esophageal variceal hemorrhages in November 1986 
and February 1987 were associated with ascites and 
hepatic encephalopathy. In May 1988, he had an 
episode of vibrio vulnificus bacteremia/cellulitis, fol-
lowed by bacterial peritonitis from a gram-positive 
coccus. Further variceal hemorrhages led to his re-
ferral to the University of Pittsburgh Medical Center 
on June 29, 1988. for urgent consideration of liver 
transplantation. 
Two days later, hepatic replacement with the liver of a 
6-HLA-antigen-mismatched 12-year-old cadaveriC 'do-
nor was carried out by means of conventional tech-
niques. The pancreas from the same donor was then 
transplanted below the transverse mesocolon and arte-
rialized with a Carrel patch that encompassed the do-
nor celiac axis and superior mesenteric artery origins. 
The Carrel patch was anastomosed to the recipient's 
infrarenal aorta. Venous outflow from the pancreas was 
directed into the recipient's superior mesenteric vein 
via a short interposition graft of donor iliac vein. Exo-
crine pancreatic secretions were drained into the recip-
ient upper gastrointestinal tract through 2 end-to-side 
anastomoses: duodeno-duodenostomy at the second 
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Figure 1. Liver-pancreas transplant operation performed on 
July 1. 1988_ Key features included the interposition of the 
transverse mesocolon between the 2 separately revascularized 
organs. delivery of the pancreas graft venous outflow into the 
host superior mesenteric vein (SMV), and the method of _-
teric drainage of pancreatic u:ocrine secretions. With slight 
modifications (e.g .• double exocrine drai_ge is not neces-
sary). the pancreas engraftment technique could be used to 
test the value of portal pancreatic venous drainage in pancre-
as-alone or pancreas-kidney recipients. PV. portal vein; IVC. 
interior vena cava. 
part of the host duodenum. and duodeno-jejunostomy 
near the host ligament of Treitz (Fig. 1). 
Immunosuppression was with cyclosporine. azathio-
prine. and prednisone to which a 14-day course ofba-
siliximab and muromonab was added to treat an early 
rejection. Thirteen weeks after transplantation. an in-
crease in serum bilirubin (peak 7.1 mg/dL) and 
transaminase concentrations (serum glutamic-oxaloa-
cetic transferase peak 400 IU) occurred that were first 
ascribed to rejection. then to recurrent HBV hepatitis. A 
stable functional state was achieved after 7-8 months. 
Since then. he has had mild to moderate increases of 
serum transaminases (usually less than twice normal) 
but with normal liver synthetic functions and bilirubin 
concentrations despite slowly worsening biopsy evi-
dence of hepatic fibrosis (last sample 2003). He was 
found to be infected with hepatitis C in 1994 and was 
unsuccessfully treated with interferon alfa. He was 
treated with lamivudine between 1997 and 2004. His 
current medications include 25 mg cyclosporine twice a 
day (trough levels frequently undetectable). 5 mg/d 
prednisone. 10 mg/d adefovir dipivoxil, 2 antihyperten-
sive drugs. and antacids. Serum creatinine concentra-
tions are normal. 
He has required no insulin therapy since his double 
organ transplant. His principal medical problems since 
1990 have been cardiovascular. for the most part re-
lated the incomplete closure of the AV defect at age 15. 
In 1995, a permanent pacemaker was inserted for the 
treatment of heart block. Small strokes began in 1997 
and were attributed to emboli passing through the in-
completely closed AV defect. He then developed pro-
gressive congestive heart failure. and a second major 
cardiac procedure was undertaken in 2001. The oper-
ation included definitive repair of the AV septal defect, 
tricuspid valve annuloplasty, porcine mitral valve re-
placement, and a single-vessel coronary artery bypass 
graft. Glucose homeostasis has been excellent through-
out. Current liver functions include a normal bilirubin 
(0.5 g/dLJ, aspartate aminotransferase (38 IUl, serum 
albumin (4.1 g/dL), and international normalization ra-
tio (1.2). The patient has been able to work. continues to 
demonstrate a sharp and ironic wit, and remains an 
avid reader of history books. 
DISCUSSION 
When the operation for this patient was planned in 
1988. liver transplantation under cyclosR0rine-based 
immunosuppression had become a widely accepted 
form of treatment. 2 In contrast, pancreas transplanta-
tion faced an uncertain future because of its excessive 
morbidity and mortality. 3 One problem was that neither 
the whole organ pancreas transplantation Originally de-
scribed by Lillehei et al.,4 nor the then more popular 
option of partial (segmental) pancreatic transplanta-
tion, were standardized operations. The principal lethal 
risks with both kinds of procedure were associated with 
enteric drainage of the graft exocrine secretions. Con-
sequently. the strategy with almost all pancreas trans-
plantations from the early 1970s to the mid-1980s was 
to divert the secretions to extra-alimentary destinations 
(e.g .• the host urinary tract or free peritoneal cavity) or 
to eliminate the secretions by blocking the ducts of 
segmental pancreas grafts (e.g.. with polymer injec-
tion).3.5 In opposition to these trends. we had urged the 
use of the whole pancreas with enteral drainage of its 
exocrine secretions via the graft duodenum. 6 Both of 
these recommendations were carried out in our 1988 
liver-pancreas reCipient with diabetes (Fig. 1). 
A second technical question was where to direct the 
venous outflow of the pancreas allograft. With the pelvic 
implantation site that remains in common use today for 
patients with diabetes who do not have liver disease. 
the pancreatic venous effluent usually is directed into 
the host systemiC circulation by anastomosis to an iliac 
vein or to the inferior vena cava. This practice has po-
tentially important undesirable implications. Glucose 
homeostasis is maintained by the liver. where insulin is 
almost completely removed from the blood with a single 
transhepatic passage. However. the insulin binding has 
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many other consequences for the liver. In the 1970s, it 
was shown that the first pass-exposure of the liver to 
endogenous or portally infused insulin is critical for 
normal maintenance of hepatic size, ultrastructure, 
function, and the capacity for regeneration. 7-11 To con-
fer the hepatotrophic benefits of insulin and other mol-
ecules from the pancreas on the cotransplanted liver of 
our 1988 recipient, the venous effluent ofthe pancreas 
graft was drained into the host superior mesenteric 
vein. 
Thus. the operation carried out in 1988 differed 
greatly from the only previous liver-pancreas trans-
plantation into a patient with diabetes. In the earlier 
case (October 3, 1979), Calne et al. 12 implanted a seg-
mental pancreas graft (body and tail) from the same 
donor in the pelvis of a liver recipient after polymer 
injection of the duct system. Venous outflow was di-
rected into the iliac vein. Glucose homeostasis was 
promptly normalized. The reCipient required resump-
tion of insulin after 1 year, but survived for 6.1 years. 
No other diabetic liver reCipients are known to have 
undergone the double organ transplantation until the 
1988 patient reported here. 
However. an en bloc allograft of the liver and pan-
creas (with the attached duodenum) was being used in 
Pittsburgh throughout the 1988-89 period as replace-
ment for the resected native upper abdominal organs of 
patients without diabetes with hepatic, pancreatic, or 
duodenal malignancies that had metastasized region-
ally.13 A total of 21 patients received these composite 
("cluster") allografts. Despite a high rate of tumor recur-
rence, the 3- to 5-year survival was >30%. All of the 21 
recipients became insulin independent and remained 
so up to the time of death or to the 3- to 5-year follow- . 
Up.14 However, graft pancreatitis was a frequent early 
complication and caused one death. 13.14 
Because of the possibility that pancreas complica-
tions could jeopardize the liver graft, the 2 organs were 
separated and transplanted individually in our 1988 
patient with diabetes, above and below the host trans-
verse mesocolon. This concern notwithstanding. recent 
reports of pancreas transplantation in 3 liver recipients 
with diabetes, 2 in Brussels15 and 1 in Leeds,16 have 
revitalized interest in the original en bloc transplant 
operation. Both groups emphasized the advantages (in-
cluding the safety) of the en bloc procedure while noting 
the scarcity of liver recipients with diabetes who had 
undergone simultaneous pancreas transplantation of 
any kind « 10 reported). In view ofthe small number of 
reported cases, it is possible that pancreas transplan-
tation is being underused in liver reCipients with diabe-
tes. 
Our policy when pancreas transplantation is used in 
a liver reCipient. whether Simultaneously or later. has 
been to route the pancreas venous drainage through 
the hepatic allograft because this provides an ideal met-
abolic environment for the new liver. 17 In turn, survival 
of the pancreas may be aided by the well-known im-
mune protective effect of the liver. 18 The perSistence for 
18 years of the still well-functioning liver allograft re-
ported here was of particular interest in view of its 
PERSPECTIVES IN LT 3 
prompt infection by HBV. and later hepatitis C virus. 
Although the HBV infection was treated with hyperim-
munoglobulin, this therapy was not standardized in 
1988. and effective antiviral drugs were not yet avail-
able. Consequently, the prognosis for disease recur-
rence was so dismal that HBV was considered at the 
time to be a relative contraindication for liver transplan-
tation by most insurance carriers and an absolute one 
by all government agenCies that funded this procedure. 
This patient beat the odds because of new HBV thera-
peutic developments that have continued to the present 
time. 
Although the foregoing anatomic/metabolic consid-
erations have been focused on the welfare of the hepatic 
allografts. they could be relevant to the health of native 
livers of reCipients with diabetes in whom the allograft 
pancreas has been transplanted alone or in combina-
tion with the kidney or other nonhepatic organs. More 
than 90% of such pancreas grafts have their venous 
effluent diverted into the systemic circulation (i.e .. 
around the liver). 5 The non physiologic drainage results 
in systemic hyperinsulinemia and has been associated 
with dyslipidemia, accelerated atherosclerosis. and in-
sulin resistance. 19 In turn, insulin resistance is of par-
ticular concern to hepatologists because it is thought to 
be a seminal factor in pre- and posttransplantation 
nonalcoholic steatohepatitis syndromes.2o 
Formal comparisons of portal vs. systemic venous 
drainage in pancreas alone and kidney-p~creas reCip-
ients 19.21.22 have not included assessment of the effects 
on the liver. At the 40th armiversary celebration of the 
first human pancreas transplantation held at the Uni-
versity of Minnesota during December 6-8, 2006, inter-
est was expressed in carrying out studies that would 
bring this important question to closure. 
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